The role of S100A14 in epithelial ovarian tumors

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3482-3496

  Cho, Hanbyoul ^a,c   Shin, Ha Yeon ^a   Kim, Sunghoon ^b,c   Kim, Jane Seon Young ^a   Chung, Joon Yong ^d   Chung, Eun Joo ^d   Chun, Kyung Hee ^c   Hewitt, Stephen M ^d   Kim, Jae Hoon ^a,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epithelial ovarian cancer; S100A14; shRNA; Tumor marker

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S 100; PROTEIN S100A14; RNA; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; S100A14 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOMA CELL; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MOTION; DISEASE COURSE; GENE SILENCING; GENETICS; METABOLISM; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903520536     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1947     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1): 43-66.
2. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001; 22(2): 255-288.
3. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 2012; 226(3): 421-426.
4. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100(1): 58-64.
5. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004; 191(3): 718-732.
6. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195(4): 451-456.
7. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001; 33(7): 637-668.
8. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003; 60(6): 540-551.
9. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004; 322(4): 1111-1122.
10. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008; 34(4): 357-364.
11. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, Spiegelman VS, Setaluri V, Mukhtar H. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci U S A. 2006; 103(40): 14825-14830.
12. Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, Crnogorac-Jurcevic T. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res. 2007; 67(18): 8633-8642.
13. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, KerkhoffC, Gerke V, Liersch R, Mesters RM, Hotfilder M, Marra A, Koschmieder S, Dugas M, Berdel WE, Serve H, Muller-Tidow C. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009; 15(1): 22-29.
14. Pietas A, Schluns K, Marenholz I, Schafer BW, Heizmann CW, Petersen I. Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the S100 family. Genomics. 2002; 79(4): 513-522.
15. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007; 27(5A): 3051-3058.
16. Sapkota D, Bruland O, Costea DE, Haugen H, Vasstrand EN, Ibrahim SO. S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9. Eur J Cancer. 2011; 47(4): 600-610.
17. Cho H, Lee YS, Kim J, Chung JY, Kim JH. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 2013; 31(9): 607-615.
18. Chen H, Ma J, Sunkel B, Luo A, Ding F, Li Y, He H, Zhang S, Xu C, Jin Q, Wang Q, Liu Z. S100A14 is a novel modulator of terminal differentiation of esophageal squamous cell carcinoma. Mol Cancer Res. 2013; doi:10.1158/1541-7786.mcr-13-0317.
19. Sapkota D, Costea DE, Ibrahim SO, Johannessen AC, Bruland O. S100A14 Interacts with S100A16 and Regulates Its Expression in Human Cancer Cells. PLoS One. 2013; 8(9): e76058.
20. Xu C, Chen H, Wang X, Gao J, Che Y, Li Y, Ding F, Luo A, Zhang S, Liu Z. S100A14,a member of EF-hand Calcium-Binding Proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem. 2013; doi:10.1074/jbc. M113.469718.
21. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5): 1511-1518.
22. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008; 198(4): 351-356.
23. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3): 433-443.
24. Yu CS, Chen YC, Lu CH, Hwang JK. Prediction of protein subcellular localization. Proteins. 2006; 64(3): 643-651.
25. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res. 2000; 261(1): 91-103.
26. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res. 2008; 6(10): 1544-1553.
27. Chen H, Yuan Y, Zhang C, Luo A, Ding F, Ma J, Yang S, Tian Y, Tong T, Zhan Q, Liu Z. Involvement of S100A14 protein in cell invasion by affecting expression and function of matrix metalloproteinase (MMP)-2 via p53-dependent transcriptional regulation. J Biol Chem. 2012; 287(21): 17109-17119.
28. Cho H, Kang ES, Hong SW, Oh YJ, Choi SM, Kim SW, Kim SH, Kim YT, Lee KS, Choi YK, Kim JH. Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. Mol Cell Biochem. 2008; 319(1-2): 189-201.
29. Cho H, Lim BJ, Kang ES, Choi JS, Kim JH. Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med. 2009; 218(2): 129-139.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3): 205-216.
31. Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res. 1998; 4(6): 1483-1487.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402-408.
33. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M. Cell migration and invasion assays. Methods. 2005; 37(2): 208-215.
34. Goodwin SC, Bonilla SC, Sacks D, Reed RA, Spies JB, Landow WJ, Worthington-Kirsch RL. Reporting standards for uterine artery embolization for the treatment of uterine leiomyomata. J Vasc Interv Radiol. 2003; 14(9 Pt 2): S467-476.